These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6322683)

  • 1. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.
    Ti TY; Fortin L; Kreeft JH; East DS; Ogilvie RI; Somerville PJ
    Antimicrob Agents Chemother; 1984 Jan; 25(1):83-7. PubMed ID: 6322683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
    Albin H; Ragnaud JM; Demotes-Mainard F; Vinçon G; Couzineau M; Wone C
    Eur J Clin Pharmacol; 1986; 31(4):479-83. PubMed ID: 3816928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.
    Patel IH; Sugihara JG; Weinfeld RE; Wong EG; Siemsen AW; Berman SJ
    Antimicrob Agents Chemother; 1984 Apr; 25(4):438-42. PubMed ID: 6329080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.
    Cohen D; Appel GB; Scully B; Neu HC
    Antimicrob Agents Chemother; 1983 Oct; 24(4):529-32. PubMed ID: 6316845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
    Albin HC; Demotes-Mainard FM; Bouchet JL; Vincon GA; Martin-Dupont C
    Clin Pharmacol Ther; 1985 Sep; 38(3):285-9. PubMed ID: 4028623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.
    Kowalsky SF; Echols RM; Parker MA
    Clin Pharm; 1985; 4(2):177-81. PubMed ID: 3987216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefotaxime disposition pharmacokinetics during peritoneal dialysis.
    Overgaard S; Løkkegaard N; Scrøder S; Fugleberg S; Nielsen-Kudsk F
    Pharmacol Toxicol; 1987 May; 60(5):321-4. PubMed ID: 3615340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.
    Kampf D; Schurig R; Weihermüller K; Förster D
    Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis.
    Lee CS; Peterson JC; Marbury TC
    J Clin Pharmacol; 1983 Jul; 23(7):274-80. PubMed ID: 6886029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose ceftriaxone kinetics in the newborn.
    Schaad UB; Hayton WL; Stoeckel K
    Clin Pharmacol Ther; 1985 May; 37(5):522-8. PubMed ID: 3987175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.
    Heim KL; Halstenson CE; Comty CM; Affrime MB; Matzke GR
    Antimicrob Agents Chemother; 1986 Jul; 30(1):15-9. PubMed ID: 3752976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
    MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
    Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of ceftriaxone in hemodialysis].
    Laville M; Mercatello A; Freney J; Pozet N; Meugnier H; Labeeuw M; Fleurette J; Zech P
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):719-23. PubMed ID: 3309803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K; Ozawa Y
    Antimicrob Agents Chemother; 1984 Nov; 26(5):647-51. PubMed ID: 6097172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic profile of ceftriaxone in man.
    Patel IH; Kaplan SA
    Am J Med; 1984 Oct; 77(4C):17-25. PubMed ID: 6093513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K
    Antimicrob Agents Chemother; 1986 Dec; 30(6):901-5. PubMed ID: 3468882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
    Merdjan H; Baumelou A; Diquet B; Chick O; Singlas E
    Br J Clin Pharmacol; 1985 Feb; 19(2):211-7. PubMed ID: 3986079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.